Tempus AI Nears Profitability, but GAAP Losses Loom

What happened

Tempus AI's fourth-quarter and full-year 2025 results show gross profit surging and adjusted EBITDA turning positive for the first time, signaling operating leverage is emerging as the company scales its diagnostics and data licensing platform. The Zacks article highlights that the company is nearing profitability, with adjusted EBITDA of $12.9 million in Q4 and improved full-year adj. EBITDA of negative $7.4 million from negative $104.7 million. However, persistent GAAP operating losses of $252.9 million in FY2025, coupled with stock-based compensation of $124.7 million excluded from adj. EBITDA, mean the company remains far from true profitability on a reported basis. The DeepValue master report maintains a WAIT rating, emphasizing that the market's pricing assumes delivery of FY2026 guidance ($1.59B revenue and $65M adj. EBITDA), but real operating leverage must show up in narrowing GAAP losses. Dilution risk also persists, with shares outstanding rising 10% to 173.2 million and an evergreen equity plan allowing up to 5% annual dilution through 2034.

Implication

For investors, the emergence of positive adj. EBITDA is a necessary but insufficient condition to buy the stock. The gap between adj. EBITDA and GAAP operating losses remains wide ($65M target vs. $253M loss), and the company's reliance on stock-based compensation (over $124M annually) means per-share value growth is pressured unless GAAP losses narrow sharply. The report's attractive entry at $40 offers a 15% downside from current levels, but the next 1-2 quarters must show GAAP operating loss run-rate falling below $150M and no new primary equity issuance to validate the thesis. If the company can deliver FY2026 guidance and simultaneously reduce GAAP losses, the stock could re-rate toward the base case of $52; failure risks a decline to $30. Until then, the WAIT rating is appropriate, with a 3-6 month reassessment window. The news does not alter the fundamental caution—positive headlines on adj. EBITDA do not bridge the GAAP loss gap or the dilution overhang.

Thesis delta

The news confirms the operating leverage narrative from the report but does not shift the investment thesis: TEM still needs to prove it can convert adj. EBITDA growth into narrowing GAAP losses while controlling dilution. The report's WAIT rating remains anchored on the need for two quarters of positive adj. EBITDA and GAAP operating loss run-rate under $150M before the risk/reward becomes favorable.